Fig. 3: The epidermal growth factor receptor (EGFR) C797S mutation results in PDK1 upregulation via the EGFR/AKT/HIF-1α axis in A549 cells.
a Immunoblot analysis results showing the levels of p-EGFR (Y1068), p-AKT Serine/Threonine Kinase 1 (AKT) (S473), p-extracellular signal-regulated kinase (ERK) (Y204), and p-signal transducer and activator of transcription 3 (STAT3) (Y705), as well as the levels of EGFR, total AKT, ERK2, STAT3, hypoxia-inducible factor (HIF)-1α, pyruvate dehydrogenase kinase (PDK)1, PDK3, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control) in EGFR-mutant A549 cells. b Immunoblot analysis of A549 EGFR19del747_750+T790M+C797S (19DMS)/EGFRL858R+T790M+C797S (RMS) cells treated with LY294002 (50 μM), U0126 (10 μM), or tofacitinib (50 μM) for 24 h. The levels of p-AKT (S473), p-ERK (Y204), and p-STAT3 (Y705), as well as the levels of total AKT, ERK2, STAT3, HIF-1α, PDK1, PDK3, and GAPDH (loading control), were measured. c Immunoblot analysis of A549 19DMS/RMS cells treated with YC-1 (50 μM) for 24 h. The expression of HIF-1α, PDK1, PDK3, and GAPDH (loading control) was measured. d Immunoblot analysis of A549 19DMS/RMS cells treated with the indicated concentrations of osimertinib for 24 h. The levels of p-EGFR (Y1068) and p-AKT (S473), as well as the levels of EGFR, total AKT, HIF-1α, PDK1, PDK3, and GAPDH (loading control), were measured. e Immunoblot analysis of A549 19DMS/RMS cells treated with osimertinib (0.1 μM) at the indicated time points. The levels of p-EGFR (Y1068) and p-AKT (S473), as well as the levels of EGFR, total AKT, HIF-1α, PDK1, PDK3, and GAPDH (loading control), were measured.
